Overview

Integrative Analysis of the Tumor Microenvironment and Optimization of the Immunotherapy Duration in Non-small Cell Lung Cancer Patients.

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Non-comparative multicentric randomized study to assess long-term benefit of PD-1 inhibition in NSCLC patients who experienced a response between 6 and 12 months after initiation of ICI (immune checkpoint inhibitor PD1/PDL-1 blockade therapy)
Phase:
Phase 2
Details
Lead Sponsor:
Institut Bergonié